In recent years, pulmonary infection caused by Klebsiella pneumoniae has been increasing in clinical practice, becoming one of the important pathogens threatening human health. Morukin, as a commonly used antibiotic, has a certain effect in the treatment of bacterial pneumonia, but the acute pulmonary inflammation caused by Morukin has also brought serious side effects to patients. Therefore, the aim of this study was to explore the molecular mechanism of SH3GL3 recombinant protein and investigate its effect on reducing acute pulmonary inflammation in the treatment of Klebsiella pneumoniae infection by modulating the STAT3/ROS signaling pathway. In this study, recombinant SH3GL3 protein was prepared by genetic engineering technology to establish an animal model of Klebsiella pneumoniae infection. The effect of recombinant SH3GL3 protein on acute pulmonary inflammation was evaluated by observing the pathological changes of lung tissue, inflammatory cell infiltration and expression levels of inflammatory factors in each group. Western blot, immunohistochemistry and other techniques were used to detect the expression and activity of STAT3 and ROS signaling pathway related proteins, in order to reveal the molecular mechanism of SH3GL3 recombinant protein in alleviating inflammation. In the SH3GL3 recombinant protein intervention group, the pathological changes of lung tissue were significantly reduced, the number of inflammatory cells was reduced, and the expression level of inflammatory factors was decreased. Further molecular mechanism studies have shown that SH3GL3 recombinant protein can significantly inhibit the phosphorylation and activation of STAT3 and reduce the production of ROS, thus inhibiting the activation of STAT3/ROS signaling pathway and alleviating pulmonary inflammation. The recombinant protein SH3GL3 effectively alleviates acute pulmonary inflammation in the treatment of Klebsiella pneumoniae infection with morukin by regulating the STAT3/ROS signaling pathway.
